The effect of drug concentration and curing time on processing and properties of calcium alginate beads containing metronidazole by response surface methodology

The purpose of present research work was to prepare calcium alginate beads containing water-soluble drug metronidazole using 3² factorial design, with drug concentration and curing time as variables. Curing time was kept as low as possible to improve entrapment with increasing drug concentration. Mostly the drugs which had been encapsulated were water insoluble to facilitate drug encapsulation; a characteristic drug release as whole process is aqueous based. Entrapment efficiency was in the range of 81% to 96% wt/wt, which decreased with decrease in polymer concentration and increase in curing time. The beads were spherical with size range between 1.4 and 1.9 mm. Scanning electron microscope (SEM) photomicrographs revealed increase in the leaching of drug crystals with increased curing time and high drug concentrations. In acidic environment, the swelling ratio was 200% in 30 minutes, but in basic medium, it increased to a maximum of 1400% within 120 minutes. In acidic medium, the swelling and drug release properties were influenced by drug solubility, whereas in phosphate buffer these properties were governed by the gelling of polymer and exhibited curvilinear and quadratic functions of both the variables, respectively.     

黑龙江地区400例乙型肝炎病毒基因分型与耐药突变研究

目的:运用基因芯片技术分析黑龙江地区乙型肝炎病毒(HBV)基因型分布特征及基因耐药变异情况。方法:随机选择2012年11月至2015年11月本医院乙型肝炎患者血清样本400例,应用PCR-反向点杂交的基因芯片技术对样本血清中HBV基因型及常见4类抗病毒药物耐药相关的多个位点进行检测,并进行数据分析。结果:400例样本中基因型分布以C型为主占83.25%(333例),B型7.25%(29例)、D型0.25%(1例)及混合基因型2.75%(11例);耐药突变位点检出188例,总耐药率为45.19%,其中突变位点236T(4.61%)提示阿德福韦酯单项耐药,耐药率为5.82%(10例),与拉米夫定耐药相关的为126例,突变位点以rt204I和(rt180M+rt240V)为主,显著高于其他抗病毒类药物,耐药风险较高。结论:黑龙江地区乙型肝炎基因分型以C为主,B型和其它混合型较少,且更容易对拉米夫定产生耐药。     

肠球菌的临床感染与耐药性分析

目的了解温州医学院附属第一医院临床分离主要肠球菌的分布及其对常用抗菌药物的耐药现状,以指导临床合理用药。方法对2008年至2011年临床分离的635株粪肠球菌和屎肠球菌的标本来源和药敏结果进行回顾性分析。结果各种临床标本中两种肠球菌的分布比例存在差异,总体以尿液标本所占比例最多,且屎肠球菌的总体分离率高于粪肠球菌。粪肠球菌对利奈唑胺、氨苄西林、万古霉素、呋喃妥因和替考拉宁的耐药率都在5．0％以下,对莫西沙星和青霉素G的耐药率也仅为7．0％和6．7％;屎肠球菌对莫西沙星、左旋氧氟沙星、环丙沙星、氨苄西林、青霉素G和红霉素的耐药率都在90．0％以上,对利奈唑胺、万古霉素、替考拉宁和奎奴敏感。粪肠球菌的多重耐药株占总数的26．4％,屎肠球菌的多重耐药株占总数的78．2％。结论粪肠球菌和屎肠球菌对15种抗菌药物的耐药情况不同,屎肠球菌具有更高的耐药率和更广的耐药谱。临床应根据药敏试验的结果合理选择抗菌药物,以防止耐药菌株的产生和播散。     

骨科患者伤口分泌物病原菌分布及耐药性分析

目的:了解我院骨科患者伤口分泌物病原菌分布及其耐药性情况,为临床上对骨科患者合理使用抗生素提供相关理论根据。方法:将2013年2月至2014年8月我院282例术后骨科患者的伤口分泌物标本接种培养,按要求分离纯菌,采用VITEK 2Compact全自动微生物分析仪进行鉴定及药敏试验。结果:282份标本中分离出致病菌186株(65.96%),其中革兰氏阴性球菌94株(50.54%),革兰氏阳性球菌83株(44.62%),真菌9株占4.83%。分离率排在前三位的致病菌分别为阴沟肠杆菌(19.35%),金黄色葡萄球菌(17.20%),表皮葡萄球菌(15.59%)。阴沟肠杆菌、大肠埃希菌、肺炎克雷伯菌对头孢唑林和氨苄西林的耐药率最高,其中阴沟肠杆菌对头孢唑林耐药率高达100%。但未发现主要革兰氏阴性球菌对亚胺培南耐药。革兰氏阳性球菌对青霉素的耐药率较高,但未发现革兰氏阳性球菌对万古霉素耐药。结论:术后骨科患者伤口优势菌种是阴沟肠杆菌,而且耐药性高;临床医生应根据病菌鉴定和药敏分析结果,对不同种类的病原菌使用不同的抗生素进行针对性治疗。     

慢性支气管炎患者下呼吸道感染病原菌分布及耐药性分析

目的:研究老年慢性支气管炎患者合并下呼吸道感染病原菌分布以及耐药性。方法:选取2009年1月到2013年12月我院收治的老年慢性支气管炎患者合并下呼吸道感染患者261例,采集所有患者的痰液,然后进行病原菌鉴定和药敏试验。结果:261例患者中,144例革兰阴性杆菌感染(55.2%),51例革兰阳性杆菌感染(19.5%),66例真菌感染(25.3%),其中混合感染者36例(13.8%)。革兰阴性杆菌以肺炎克雷伯菌最多(18.4%),革兰阳性杆菌以金黄色葡萄球菌最多(9.2%)。革兰阴性杆菌对亚胺培南的耐药性最低,其次是头孢哌酮和阿米卡星,对氨苄西林耐药率最高。金黄色葡萄球菌和表皮葡萄球菌对青霉素的耐药率均为100.0%,均对万古霉素敏感,其次是对环丙沙星敏感。结论:老年慢性支气管炎患者合并下呼吸道感染以革兰阴性杆菌感染为主,真菌和混合感染也占一定的比例,应该引起注意。     

奇异变形杆菌耐药性的4年监测及碳青霉烯类耐药株的耐药机制研究

目的了解本地区2007年到2010年奇异变形杆菌的临床分布与常用抗菌药物的耐药情况,了解碳青霉烯类耐药菌株可能存在的机制。方法回顾分析2007年到2010年临床分离奇异变形杆菌的资料及整体耐药情况;对保存的耐亚胺培南（IPM）、美罗培南（MEM）或厄他培南（ETP）的菌株进行复苏,并做Hoage试验进行产碳青霉烯酶的确认,同时对试验菌株进行耐药基因的PCR扩增检测。结果2007年到2010年,奇异变形杆菌在临床各送检样本中以痰液分离率最高：51．1％、34．4％、22．1％和35．4％,其次为尿液：14．3％、28．O％、34．9％和33．6％;耐药监测分析显示,4年间对喹诺酮类、青霉素类、头孢菌素类及氨基糖苷类耐药率相对较高且较为稳定;对碳青霉烯类耐药最低但增加明显,亚胺培南从2007年的1．8％升到2010年的16．1％,美罗培南从2007年的1．7％升到2010年的16．8％。15株耐碳青霉烯类菌株中,Hoage试验阳性7株,6fn。基因阳性11株,blaCTX-M基因阳性13株。结论本地区奇异变形杆菌对临床常用的抗菌药物均有较高的耐药性,对碳青霉烯类药物的耐药率最低,但增加明显。位于质粒上的blaKPc基因所产生的碳青霉烯酶和6如cTx-M基因所产生的超广谱β-内酰胺酶是本菌对β-内酰胺类抗菌药物耐药的主要原因,临床应引起高度重视。     

育龄妇女泌尿生殖道无乳链球菌感染情况与耐药性分析

目的探讨育龄妇女泌尿生殖道无乳链球菌感染情况与耐药性。方法选择3 000例在我院就诊的育龄期妇女,所有患者送检泌尿道或生殖道标本,进行无乳链球菌培养及药物敏感性试验,探讨育龄妇女泌尿生殖道无乳链球菌感染情况及耐药性。结果 3 000例育龄妇女中177例感染无乳链球菌,感染率5.90%,其中肾内科患者感染率最高,达到8.97%。2012至2015年育龄期妇女无乳链球菌感染率逐年增加。无乳链球菌对四环素、克林霉素、红霉素、左氧氟沙星耐药性较高,分别达到80.80%、60.45%、56.50%、45.20%。无乳链球菌对头孢曲松、头孢他啶、亚胺培南、万古霉素未产生耐药性。结论育龄妇女无乳链球菌感染率较高,呈逐年上升趋势,防治形势严峻,无乳链球菌对多种常用抗生素耐药率较高,应根据药敏结果合理使用抗生素。     

Growth slow-down and growth arrest of human colon carcinoma cells HCT-8 in vitro after exposure to 5-fluoro-2'-deoxyuridine

Abstract. Cellular heterogeneity in drug response denotes a mixed response among individual cells in a drug treated population. Individual cell responses may be more complex than 'cell kill'and 'no response'. In this study we employed a colony formation assay and high-resolution image analysis to detect the various responses such as immediate and delayed cessation of growth, growth delay and growth slow-down, at the level of the individual colony. The evaluation was carried out using a human ileocaecal adenocarcinoma cell line (HCT-8) and the anti-tumour agent 5-fluoro-2'-deoxyuridine (FdUrd). In the presence of a drug concentration which, in standard monolayer assays, inhibits the growth to about 50% (IC₅₀) only about 20% of the colonies ceased to grow and the remaining colonies grew at a growth rate of about 70% of control. At an FdUrd concentration which, in standard monolayer assays, reduced growth by >90% (>IC₉₀), about 50% of the cells grew, with growth rates of about 30% of control. The slowing of growth, most prominent at lower drug concentrations, should be considered in determining mechanisms of drug action at the individual cell level. In clinical situations in which high drug doses are precluded by toxicity to normal tissues, growth slow-down may play a significant role in tumour response.     

医院工作人员鼻腔葡萄球菌带菌状况年度推移的调查报告

本文报道1989年从202名医院工作人员鼻腔分离葡萄球菌的带菌状况和药敏性检测结果。并将此结果同作者等于1985年对200名同类人员检测的结果相比较,作了年度推移的调查分析发现1989年度的总带菌率(76.6％)比1985年度(84.5％)略有下降,但其中的金黄色葡萄球菌带菌率却从1985年的7.5％上升为10.4％。从1989年和1985两个年度的调查中,均发现临床科室人员金葡菌带菌率高于其它辅助科室人员,说明医务人员带菌率与接触病人成正相关关系。分离菌株对12种抗菌药物的耐药性检测结果显示,1989年分离菌株对其中9种的敏感性下降,并且从耐药谱显示出对5种抗菌药物耐药的多重耐药菌株明显增多。另从金葡菌的耐药情况,也看出1989年的耐药率高于1985年菌株。还在1989年分离的金葡菌中出现25％的耐甲氧西林菌株。     

Mannosylated liposomes bearing Amphotericin B for effective management of visceral Leishmaniasis

The cationic and mannosylated liposomes were prepared using the cast film method and compared for their antileishmaniasis activity. The surface of the Amphotericin B (Amp B)-bearing cationic multilamellar liposomes was covalently coupled with p-aminophenyl-α-D-mannoside using glutaraldehyde as a coupling agent, which was confirmed by agglutination of the vesicles with concanavalin A. The prepared liposomes were characterized for shape, size, percent drug entrapment, vesicle count, zeta potential, and in vitro drug release. Vesicle sizes of cationic and mannosylated liposomes were found to be 2.32 ± 0.23 and 2.69 ± 0.13 μm, respectively. Zeta potential of cationic liposomes was higher (30.38 ± 0.3 mV), as compared to mannosylated liposomes (17.7 ± 0.8 mV). Percentage drug release from cationic and mannose-coupled liposomes was found to be 45.7% ± 3.1 and 41.9% ± 2.8, respectively, after 24 hours. The in vivo antileishmanial activity was performed on Leishmania donovani-infected golden hamster, and results revealed that Amp B solution was reduced by 42.5 ± 1.8% in the parasite load, whereas the placebo cationic liposomes and drug-containing cationic liposomes showed a reduced parasite load (i.e., 28.1 ± 1.5 and 61.2 ± 3.2%, respectively). The mannose-coupled liposomes showed a maximum reduction in parasite load (i.e., 78.8 ± 3.9%). The biodistribution study clearly showed the higher uptake of mannosylated liposomes in the liver and spleen and hence the active targeting to the reticular endothelial system, which, in turn, would provide a direct attack of the drug to the site where the pathogen resides, rendering the other organs free and safe from the toxic manifestations of the drug.     

Cross-linked guar gum microspheres: A viable approach for improved delivery of anticancer drugs for the treatment of colorectal cancer

In the present work, guar gum microspheres containing methotrexate (MTX) were prepared and characterized for local release of drug in the colon, which is a prerequisite for the effective treatment of colorectal cancer. Guar gum microspheres were prepared by the emulsification method using glutaraldehyde as a cross-linking agent. Surface morphological characteristics were investigated using scanning electron microscopy. Particle size, shape, and surface morphology were significantly affected by guar gum concentration, glutaral dehyde concentration, emulsifier concentration (Span 80), stirring rate, stirring time, and operating temperature. MTX-loaded microspheres demonstrated high entrapment efficiency (75.7%). The in vitro drug release was investigated using a US Pharmacopeia paddle type (type II) dissolution rate test apparatus in different media (phosphate-buffered saline [PBS], gastrointestinal fluid of different pH, and rat cecal content release medium), which was found to be affected by a change to the guar gum concentration and glutaraldehyde concentration. The drug release in PBS (pH 7.4) and simulated gastric fluids followed a similar pattern and had a similar release rate, while a significant increase in percent cumulative drug release (91.0%) was observed in the medium containing rat cecal content. In in vivo studies, guar gum microspheres delivered most of their drug load (79.0%) to the colon, whereas plain drug suspensions could deliver only 23% of their total dose to the target site. Guar gum microspheres showed adequate potential in achieving local release of drug in in vitro release studies, and this finding was further endorsed with in vivo studies. Published: September 8, 2006     

Quercetin-containing self-assemble proliposome preparation and evaluation

The purpose of this study was to develop a liquid self-assemble proliposome for quercetin oral delivery. This liquid proliposome was prepared by dissolving phospholipids, surfactants and drug in ethanol. There was only one step in the preparation process of this liquid self-assemble proliposome and no special devices were required. The mechanism about proliposome transformation was discussed. Quercetin proliposomes with different cremorphor RH40 concentrations (0%, 20%, 23%, 26%, 30%) were prepared. The particle size and polydispersity index decreased as cremorphor RH40 concentration increased. Meantime, the drug entrapped efficiency decreased slightly with an increase in cremorphor RH40 concentration. The in vitro drug release showed prolonged drug release in case of proliposome and the release of quercetin was slower when cremorphor RH40 concentration was higher. The absorption of quercetin and its in vivo bioavailability were significantly improved by proliposome, which was evidenced by the in situ intestinal absorption and pharmacokinetic study. Besides, the obtained quercetin proliposome was with good stability when stored at room temperature. In conclusion, quercetin liquid self-assemble proliposome was successfully prepared. It could transform into liposomal vesicle with satisfied particle size and polydispersity index instantly when cremorphor RH40 was added. Cremorphor RH40 concentration in the formulation should below 26% to get higher drug entrapped efficiency (>90%) and less irritation. The drug release was affected by the cremorphor RH40 concentration and the required drug release could be obtained by adjusting cremorphor RH40 content. The enhanced bioavailability showed liquid self-assemble proliposome could be a promising vehicle for the oral delivery of quercetin.     

5种大肠埃希氏菌Col质粒接合传递实验研究

以5种61株Col~ 大肠埃希氏菌为供体,与受体E.Coli K_(12)进行接合实验,结果有16株供体菌的Col质粒传递给K_(12),占25.4％。其中NPEC、ETEC、EPEC、EIEC、EAEC的传递比率分别是8/22、 4/21、2/15、1/2、1/1。按传递方式分类,52株耐药供体菌有10株的Col质粒和耐药标记(或R质粒)发生共同传递,占19.2％,伴发Col质粒传递的耐药标记有8种,其中TC、SM、COS、KM的并发传递率较高(16—20％)。不同耐药标记菌株的Col质粒传递率范围在0—66.7％。在8株敏感菌和1株耐药菌中有6株Col质粒发生单独传递,占66.7％。实验发现4个配对组的Col质粒和R(r)质粒发生分离而独自传递。本文分析了Col质粒传递方式和耐药性的关系,同时讨论了接合传递的不同方法。为阐明和研究R~ Col~ 肠道菌的演变及其对正常菌群生态平衡的影响提供遗传学依据。     

A POLAROGRAPHIC METHODOLOGY FOR CONTINUOUS NON-DESTRUCTIVE MONITORING OF DRUG RELEASE FROM LIPOSOMES

A simple methodology based on the differential pulse polarography (DPP) was developed for non-destructive monitoring of drug release from liposomes. The methodology was also capable of determining not only the released material that remained free in the liposomal suspension but also the amount of the drug which was eventually adsorbed on the vesicles surface after its release from the liposomes. Based on this methodology the release kinetics of encapsulated chlorothiazide in 5 mg ml^?1 DRV liposomes was studied at 37°C at pH 7.4. The results were compared to those obtained by centrifuging the DRV sample and measuring the free drug in the supernatant solution with UV-spectroscopy. Approximately 70% of the initially encapsulated drug were released within 24 h of which ca. 46% were subsequently adsorbed on vesicles' surface.     

Effects of three mydriatic drug regimens on pupil size in rhesus (Macaca mulatta) and African green monkeys (Chlorocebus aethiops)

BACKGROUND: Human mydriatric drug use in non-human primates (NHPs) has been documented but not quantified and compared for effectiveness. The objective of this study was to determine which drug regimen provided the most effective and consistent mydriatic effect for ophthalmologic examinations and other procedures. Secondary objectives were to determine average time to maximum dilation and whether species differences existed. METHODS: Twelve rhesus and 12 African green monkeys were randomly assigned to one of six treatment combinations to test the mydriatic effects of three drug regimens: (1) tropicamide 1% (T); (2) tropicamide 1% and phenylephrine hydrochloride 2.5% (TP); and (3) tropicamide 1%, phenylephrine HCL 2.5% and cyclopentolate 1% (TPC). Left and right eyes of each monkey received a different drug regimen, depending on random assignment. RESULTS: TPC showed a significantly larger mydriatic response in both species than T alone. Average time to maximum dilation with all three drug regimens was 50-60 minutes. Rhesus had a larger response to the mydriatic drug regimens than the African green monkeys. CONCLUSIONS: The TPC regimen had the largest and longest lasting mydriatic effect in both species.     

Determination of free and liposomal Amphotericin B in human plasma by liquid chromatography–mass spectroscopy with solid phase extraction and protein precipitation techniques

Amphotericin B is available in various drug delivery systems such as cholesteryl sulfate complex, as lipid complex, and as liposomal formulation. The separation and measurement of free drug (drug which is not bound with liposomal lipids) and liposomal drug (drug which is entrapped in liposomes) in the human plasma after injection of liposomal Amphotericin B is of prime importance due to toxicity concerns. A robust, specific and sensitive method has been developed to effectively separate and then quantify the free drug and liposomal drug, present in human plasma. This method utilizes solid phase extraction Oasis HLB cartridges, which retains the free drug and the liposomal Amphotericin B was eluted from the cartridge in first step. The eluted liposomal Amphotericin B was then extracted from lipids by protein precipitation method using 2% dimethylsulfoxide (DMSO) in acetonitrile. After separation and extraction, the quantification of free and liposomal fractions of Amphotericin B was performed by HPLC–MS–MS technique. The chromatographic separation was performed using Chromolith Performance RP 18e column. The mobile phase composed of 5 mM ammonium acetate, methanol and acetonitrile and a gradient elution program was used. The calibration curves were found to be linear for free Amphotericin B (0.25–15.0 μg/ml) and liposomal Amphotericin B (1.0–100.0 μg/ml). The recovery was about 96% for free Amphotericin B and about 92% for liposomal Amphotericin B. Recoveries were consistent over the linearity ranges defined. The intra-batch and inter-batch accuracy and precision fulfilled the international requirements. The stability of free and liposomal Amphotericin B was assessed under different storage conditions.     

Reduction in polypharmacy for epilepsy.

A two-year prospective study of 40 adult outpatients with chronic epilepsy was carried out in which blood drug concentrations were monitored, and anticonvulsant polypharmacy was reduced to treatment with a single drug in 29 patients (72%). In the year after the reduction of treatment the control of seizures was improved in 16 patients (55%), unchanged in eight(28%), and worse in five (17%). Mental function was improved in 16 (55%). The main reason for failure to reduce to or maintain treatment with a single drug was exacerbation of seizures during the difficult withdrawal period, especially in patients with frequent seizures, taking several drugs, or with additional neuropsychological handicaps. It is more difficult to reduce polypharmacy than to avoid it in the first place. Polypharmacy may sometimes aggravate control of seizures.     

The Resistance Analysis of Ureaplasma urealyticum and Mycoplasma hominis in Female Reproductive Tract Specimens

The aim of this study was to analyze the drug resistance of Ureaplasma urealyticum (Uu) and Mycoplasma hominis (Mh) in female reproductive track from 2007 to 2011 in Hangzhou. Antibiotics sensitivity test in Mycoplasma, which was isolated in clinics from 2007 to 2011 were analyzed retrospectively. The detection of Mycoplasma during 2007–2011 was 20,146 (54.37 %), of which the single infection rate of Uu was 42.08 %, of Mh 1.26 %, and of Uu+Mh was 11.02 %. The drug resistance rate of Uu was increased significantly in ofloxacin in 2007 (41.80 %), 2008 (45.94 %), 2009 (46.07 %), 2010 (50.36 %), and 2011 (53.22 %) (P < 0.05). The resistance rate to ciprofloxacin was significantly increased in 2007 (67.15 %), 2008 (67.44 %), 2009 (73.00 %), 2010 (75.28 %), and 2011 (75.28 %) (P < 0.05). Exceptionally, the resistance rates of the other antibiotics were low. The drug resistance rate of Uu was significantly increased with quinolones at increasing tendency. It is necessary to monitor the local drug resistance rate of Uu regularly to provide reasonable guidelines in clinics.     

胸腹水培养中的病原菌分布及耐药性分析

目的了解胸腹水培养中病原菌的分布和耐药情况,为临床合理用药提供依据。方法通过回顾性分析中山市第二人民医院住院部自2011年1月至2013年11月送检的胸腹水标本细菌培养及药敏资料。结果在494份胸腹水标本中共检出47株病原菌,总阳性率为9.5%;其中326例胸水分离出病原菌28例,阳性率为8.59%,胸水培养中革兰阳性菌占67.86%,革兰阴性菌占32.12%,菌种较为分散;168例腹水分离出病原菌19例,阳性率为11.31%,腹水培养中革兰阴性菌占73.68%,革兰阳性菌占26.32%。检出革兰阴性病原菌对氨苄西林和四环素耐药率较高,对阿米卡星、美罗培南和亚胺培南敏感。检出革兰阳性病原菌对氨苄西林、头孢西丁和红霉素耐药率高,对万古霉素、替考拉宁和吗啉噁酮敏感。结论应重视胸腹水标本的细菌学检查,依据药敏试验合理使用抗菌药物,减少细菌的耐药率。